Share

March 26, 2019; 92 (13) Article

Socioeconomic status and disability progression in multiple sclerosis

A multinational study

Katharine E. Harding, Mark Wardle, Robert Carruthers, Neil Robertson, Feng Zhu, Elaine Kingwell, Helen Tremlett
First published February 22, 2019, DOI: https://doi.org/10.1212/WNL.0000000000007190
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
254

Share

Article Information

vol. 92 no. 13 e1497-e1506
DOI: 
https://doi.org/10.1212/WNL.0000000000007190
PubMed: 
30796140
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received September 7, 2018
  • Accepted in final form November 16, 2018
  • First Published February 22, 2019.

Article Versions

Copyright & Usage: 
© 2019 American Academy of Neurology

Author Disclosures

    1. Katharine E. Harding, PhD,
    2. Mark Wardle, MD,
    3. Robert Carruthers, MD,
    4. Neil Robertson, MD,
    5. Feng Zhu, MSc,
    6. Elaine Kingwell, PhD and
    7. Helen Tremlett, PhD
  1. Katharine E. Harding, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Travel grant from Novartis UK to attend ECTRIMS 2018 in Berlin.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. Honoraria from Biogen UK to speak at a meeting

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Novartis UK.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Mark Wardle, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Robert Carruthers, MD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1), Sanofi, 2) Biogen, 3) Novartis

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1) Roche, 2) EMD Serono, 3) Sanofi, 4) Biogen, 5) Novartis, 6) Teva

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1) Teva Innovation Canada, 2) Roche Canada, 3) Novartis, 4) MedImmune, 5) EMD Serono, 6) Roche, 7) Genentech

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Neil Robertson, MD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Behring CSL speaker honoraria Biogen speaker honoraria Novartis speaker honoraria Genzyme speaker honoraria

    Editorial Boards:

    1. Journal of Neurology, Journal club editor May 2012 to current

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Multiple Sclerosis Society of Great Britain and Northern Ireland

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Feng Zhu, MSc,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Elaine Kingwell, PhD and
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Helen Tremlett, PhD
    8. Scientific Advisory Boards:

    1. All non-profit: ? National US surveillance system for MS. 2013-present. Invited by the US National MS Society to form an advisory group to enable the development of a national surveillance system capable of tracking the incidence and prevalence of MS. Monthly teleconferences; one face-to-face meeting: Atlanta, Georgia (March 2014) Status: Bipartisan legislation introduced to Congress - ?Advancing Research for Neurological Diseases Act, H.R. 292.?to guide the Centers for Disease Control and Prevention in tracking the incidence and prevalence of neurological diseases, including Multiple Sclerosis and Parkinson?s disease [13th-Jan-2015; http://burgess.house.gov/blog/? postid=397459]

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Helen Tremlett is the Canada Research Chair for Neuroepidemiology and Multiple Sclerosis. Current research support received from the National Multiple Sclerosis Society, the Canadian Institutes of Health Research, the Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation. In addition, in the last five years, has received research support from the Multiple Sclerosis Society of Canada (Don Paty Career Development Award); the Michael Smith Foundation for Health Research (Scholar Award) and the UK MS Trust; speaker honoraria and/or travel expenses to attend CME conferences from the Consortium of MS Centres (2013, 2018), the National MS Society (2014, 2016, 2018), ECTRIMS (2013, 2014, 2015, 2016, 2017, 2018), Biogen Idec (2014), American Academy of Neurology (2013, 2014, 2015, 2016). All speaker honoraria are either declined or donated to an MS charity or to an unrestricted grant for use by HT?s research group.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Canada Foundation for Innovation (CFI); Canadian Institutes of Health Research [#363635 (co-PI); #190898 (PI); #404791; #387503; #388480 (all as PI); #MOP-82738 (PI) and MOP- 119393 (PI) and MOP-106607 (PI)]; the US National Multiple Sclerosis Society (Operating grants: 2012-15; 2014-17), the Multiple Sclerosis Society of Canada (2015-18: EGID #2624 (PI); 2016-18: EGID #2680 (co-PI); ) the The Multiple Sclerosis Scientific and Research Foundation (2015-18 (PI)); Canada Research Chair in Neuroepidemiology and Multiple Sclerosis

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Faculty of Medicine (Neurology) and Djavad Mowafaghian Centre for Brain Health (K.E.H., R.C., F.Z., E.K., H.T.), University of British Columbia, Vancouver, Canada; Institute of Psychological Medicine and Clinical Neuroscience (K.E.H., N.R.), Cardiff University, University Hospital of Cardiff; and Helen Durham Centre for Neuroinflammatory Disease, Department of Neurology (M.W., N.R.), University Hospital of Wales, Heath Park, Cardiff, UK.
  1. Correspondence
    Dr. Harding katharineharding{at}doctors.org.uk
View Full Text

Article usage

Article usage: February 2019 to May 2022

AbstractFullPdfSource
Feb 2019762032Highwire
Mar 20198333152Highwire
Apr 20193692620Highwire
May 2019200712Highwire
Jun 2019124712Highwire
Jul 2019101711Highwire
Aug 20197222Highwire
Sep 20198115Highwire
Oct 2019111126Highwire
Nov 201912533Highwire
Dec 20197113Highwire
Jan 20209033Highwire
Feb 202013176Highwire
Mar 20205574Highwire
Apr 202010065Highwire
May 20207444Highwire
Jun 202010189Highwire
Jul 20208974Highwire
Aug 202010154Highwire
Sep 202011046Highwire
Oct 202071176Highwire
Nov 20208231Highwire
Dec 20204444Highwire
Jan 20216634Highwire
Feb 202111557Highwire
Mar 20219221Highwire
Apr 20218910Highwire
May 202110265Highwire
Jun 20216263Highwire
Jul 20219451Highwire
Aug 20218423Highwire
Sep 202193231Highwire
Oct 202115210Highwire
Nov 202113551Highwire
Dec 202112111Highwire
Jan 20227543Highwire
Feb 20227514Highwire
Mar 202213663Highwire
Apr 202217021Highwire
May 20227632Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me